kent holtorf bpc 157 Talking Biotech #491 is about the emerging roles of therapeutic peptides, with Dr. Karsten Eastman of Sethera Tune in to Dr. Kent
Description
Research References Lau DCW, et al
The Rights and Wrongs of Zebrafish: Behavioral Phenotyping of Zebrafish
Andrew Schneider today!

[8] Novo Nordisk announced late at the 2025 European Association for the Study of Diabetes (EASD) annual meeting that in the REDEFINE 1 study, [9] cagrilintide provided clinically significant weight loss, with a mean reduction in body weight of 11.8% compared to 2.3% with placebo after 68 weeks, considering adherence of all participants to treatment
